CTLA4 and melanoma: Antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1/programmed death ligand-1 (PD-1/PD-L1) are already being used clinically in a range of malignancies, including melanoma, where they have had very positive effects [81,82,83,84].